Immunomedics mulls veltuzumab options as Takeda ends deal amid dispute
This article was originally published in Scrip
The US firm Immunomedics has regained all global rights to veltuzumab after Takeda terminated a licensing deal for the anti-CD20 monoclonal antibody.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.